首页> 美国卫生研究院文献>other >Discovery of Methyl 4′-Methyl-5-(7-nitrobenzoc125oxadiazol-4-yl)-11′-biphenyl-3-carboxylate an Improved Small-Molecule Inhibitor of c-Myc–Max Dimerization
【2h】

Discovery of Methyl 4′-Methyl-5-(7-nitrobenzoc125oxadiazol-4-yl)-11′-biphenyl-3-carboxylate an Improved Small-Molecule Inhibitor of c-Myc–Max Dimerization

机译:改进的小分子抑制剂4-甲基-5-(7-硝基苯并c 125恶二唑-4-基)-11-联苯 -3-羧酸甲酯的发现-Myc–Max二聚化反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

c-Myc is a bHLH-ZIP transcription factor that is responsible for the transcription of a wide range of target genes involved in many cancer-related cellular processes, such as proliferation, differentiation, apoptosis and metabolism. Over-expression of c-Myc has been observed in, and directly contributes to, a variety of human cancers including those of the hematopoietic system, lung, prostate and colon. To become transcriptionally active, c-Myc must first dimerize with Max via its own bHLH-ZIP domain. A proven strategy towards the inhibition of c-Myc oncogenic activity is to interfere with the structural integrity of the c-Myc–Max heterodimer. The small-molecule 10074-G5 is an inhibitor of c-Myc–Max dimerization (IC50 = 146 μM) that operates by binding and stabilizing c-Myc in its monomeric form. Herein, we report on our on-going efforts to optimize the c-Myc–Max inhibitory activity of 10074-G5-related molecules in vitro and in cancer cells that over-express c-Myc. Specifically, we have identified a congener of 10074-G5, termed 3jc48-3, that is about five times as potent (IC50 = 34 μM) at inhibiting c-Myc–Max dimerization as the parent compound. In addition, 3jc48-3 exhibited an approximate two-fold selectivity for c-Myc–Max heterodimers over Max–Max dimers, suggesting that, like its predecessor, its mode of action is through binding c-Myc. 3jc48-3 inhibited the proliferation of c-Myc-over-expressing HL60 and Daudi cells with single-digit micromolar IC50 values by causing growth arrest at the G0/G1 phase. Furthermore, co-immunoprecipitation studies indicated that 3jc48-3 inhibits c-Myc–Max dimerization in cells, which was further substantiated by the specific silencing of a c-Myc-driven luciferase reporter gene. Finally, unlike previously described 10074-G5 analogues, which are rapidly released and/or metabolized by cells following their uptake, 3jc48-3’s intracellular half-life was >17 h. Collectively, these data demonstrate 3jc48-3 to be one of the most potent cellularly active c-Myc inhibitors reported to date.
机译:c-Myc是一种bHLH-ZIP转录因子,负责转录与许多癌症相关的细胞过程(例如增殖,分化,凋亡和代谢)有关的多种靶基因。已在多种人类癌症中观察到c-Myc的过度表达,并直接导致这些人类癌症,包括造血系统,肺癌,前列腺癌和结肠癌。为了具有转录活性,c-Myc必须首先通过其自身的bHLH-ZIP域与Max二聚。抑制c-Myc致癌活性的一种行之有效的策略是干扰c-Myc-Max异二聚体的结构完整性。小分子10074-G5是c-Myc-Max二聚化抑制剂(IC50 = 146μM),其通过以单体形式结合和稳定c-Myc来发挥作用。在此,我们报告了我们正在进行的努力,以优化体外和过度表达c-Myc的癌细胞中10074-G5相关分子的c-Myc-Max抑制活性。具体来说,我们已经确定了10074-G5的同类物,称为3jc48-3,其抑制c-Myc-Max二聚作用的效力约为母体化合物的五倍(IC50 = 34μM)。另外,3jc48-3对c-Myc-Max异二聚体的选择性是对Max-Max二聚体的大约两倍,这表明,与其前任一样,其作用方式是通过结合c-Myc。 3jc48-3通过导致G0 / G1期生长停滞,以一位数的微摩尔IC50值抑制了过度表达c-Myc的HL60和Daudi细胞的增殖。此外,免疫共沉淀研究表明3jc48-3抑制细胞中c-Myc-Max二聚化,这由c-Myc驱动的荧光素酶报道基因的特异性沉默进一步证实。最后,与先前描述的10074-G5类似物不同,3jc48-3的类似物在摄取后迅速被释放和/或被细胞代谢,因此3jc48-3的细胞内半衰期> 17 h。这些数据共同证明3jc48-3是迄今为止报道的最有效的细胞活性c-Myc抑制剂之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号